Mylan has been allowed to challenge Neurim's melatonin patent at trial following a ruling by the High Court of England and Wales that the generic drug maker did not contravene the legal principle of estoppel.
PeriRx has been hit with sanctions over its conduct after its breach of licensing suit failed in a patent licensing dispute against the University of California.
Gilead Sciences has sued an array of pharmaceutical suppliers and distributors accusing them of forming a counterfeiting network and allegedly selling fake versions of its HIV medications.
Genentech has gained a win in a suit claiming that its haemophilia treatment Hemlibra infringes a patent owned by Takeda subsidiary, Baxalta, after a US federal judge held that parts of the patent were invalid.
Oral diagnostics company PeriRx has lost a patent licensing suit against the University of California and research company RNAmeTRIX, claiming that they had breached sublicensing agreements.
Teva Pharmaceuticals has failed to persuade a federal judge in Massachusetts that Eli Lilly should be penalised over its discovery search related to a patent dispute concerning a migraine treatment.
Roche unit Chugai failed to persuade the US Patent Trial and Appeal Board that it should not institute inter partes reviews of a patent covering Actemra, a treatment for arthritis under the NHK/Fintiv rule.
A former Monsanto employee has pled guilty to conspiring to steal trade secrets from the biotech company in order to share the information with the Chinese government.
Sarepta Therapeutics won’t be able to rely on a “safe harbour” provision to protect its gene therapy invention from a patent infringement suit from biotech Regenxbio and the University of Pennsylvania, a Delaware court has ruled.
Former GlaxoGlaxoSmithKline scientists conspired to steal trade secrets to benefit the Chinese firm, Renopharma, according to the US Department of Justice.